NIH Launches Clinical Trial to Test Antibody Treatment in Hospitalized COVID-19 Patients | NIH: National Institute of Allergy and Infectious Diseases

NIH Launches Clinical Trial to Test Antibody Treatment in Hospitalized COVID-19 Patients | NIH: National Institute of Allergy and Infectious Diseases

NIH Launches Clinical Trial to Test Antibody Treatment in Hospitalized COVID-19 Patients

NIAID is supporting a set of adaptive treatment studies for COVID-19. The trial called ACTIV-3 will test therapeutics in volunteers with more severe cases of COVID-19. At first, these hospitalized volunteers will receive an experimental monoclonal antibody treatment in addition to the standard of care. This trial may also be expanded to test additional therapeutics later.